Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064% + Enstilar® foam (LEO Pharma Inc.)
Phase 3Completed 3 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Psoriasis Vulgaris
Conditions
Psoriasis Vulgaris
Trial Timeline
Oct 31, 2018 → Mar 17, 2020
NCT ID
NCT03731091About Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064% + Enstilar® foam (LEO Pharma Inc.)
Calcipotriene/ betamethasone dipropionate topical foam, 0.005%/0.064% + Enstilar® foam (LEO Pharma Inc.) is a phase 3 stage product being developed by Glenmark Pharmaceuticals for Psoriasis Vulgaris. The current trial status is completed. This product is registered under clinical trial identifier NCT03731091. Target conditions include Psoriasis Vulgaris.
What happened to similar drugs?
20 of 20 similar drugs in Psoriasis Vulgaris were approved
Approved (20) Terminated (3) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03731091 | Phase 3 | Completed |
Competing Products
20 competing products in Psoriasis Vulgaris